A 12-week, multicenter, open label study to evaluate the effectiveness and safety of donepezil hydrochloride (E2020) in subjects with mild to severe Alzheimer's disease residing in an assisted living facility

Trial Profile

A 12-week, multicenter, open label study to evaluate the effectiveness and safety of donepezil hydrochloride (E2020) in subjects with mild to severe Alzheimer's disease residing in an assisted living facility

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2013

At a glance

  • Drugs Donepezil (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 02 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Actual initiation date changed from Dec 2007 to Jan 2008 as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top